Treatment of the tumour cells with neutral sphingomyelinase drastically reduced the amount of wild-type p53 fibrosarcoma cell proliferation over 72 h in a clear dose–response (0.2–1.0 U ml−1 nSMase). This evidence concerns the gene SMPD2 and neoplasm.